2026-09-25

Ask where the fight against antimicrobial resistance (AMR) begins, and the prescription pad or the pharmacy counter will usually come first to mind. Yet, both sit near the visible end of a much longer chain. Before an antibiotic reaches a healthcare professional, it has already passed through formulation, manufacturing controls, quality testing and regulatory oversight. What happens at each of those stages ultimately determines the conditions under which the medicine reaches the patient.

That wider chain is particularly relevant this year. World Pharmacists Day carries the global theme “Empowering Pharmacists for Healthier Futures”, while India’s National Pharmacy Week carries the overarching mission of “Swasth Bharat: Combating Antimicrobial Resistance”. The 2 themes converge on a problem that can no longer be addressed at a single point in the healthcare system. AMR is a system-wide challenge, and the response has to be equally broad.

The conversation around resistance has rightly focused on inappropriate prescribing, unnecessary antibiotic use and self-medication. Those remain critical areas. However, the latest AMR Sameeksha from the World Health Organization (WHO) India shows how much wider the field has become, spanning genomic understanding of Indian clinical isolates, efforts to improve antibiotic prescribing among community physicians, drug-resistant bacterial infections in children and food safety.

The implication is straightforward: controlling AMR requires more than caution at the point of use. It requires greater precision across the system that produces, tests, prescribes, dispenses and monitors the antibiotic.

The Medicine Comes First

Antibiotic manufacturing is not a volume exercise in which consistency can be left to an end-of-line inspection. Formulation characteristics, process controls, environmental conditions, testing and quality assurance determine whether a product continues to perform within its established specifications from one batch to the next.

That becomes particularly important for specialised formulations. Medicef Pharma's work with Amoxicillin and Clavulanic Acid formulations has reinforced the importance of manufacturing discipline when a product is expected to perform within tightly defined parameters.

The distinction matters. Quality manufacturing alone will not solve AMR, and resistance should not be attributed to manufacturing quality without evidence. But responsible antibiotic use cannot depend on a pharmaceutical supply chain in which consistency, compliance and control are treated as secondary considerations.

The stewardship conversation therefore has to extend beyond prescribing and into the manufacturing environment itself.

Pharmacy is Another Control Point

The same principle applies once the medicine leaves the manufacturing environment.

A pharmacist is not simply the final point through which an antibiotic passes. The pharmacy is where a prescription becomes a medicine in the hands of a patient. Appropriate dispensing, patient counselling and reinforcement of responsible antibiotic use therefore become part of the wider stewardship framework.

The pharmacist cannot carry the burden of AMR alone. But their position within the chain gives them a defined role in ensuring that the decision made at the prescribing stage is carried through appropriately to the patient.

Diagnostics Close Another Gap

Diagnostics provide another critical link in that chain. Improving antibiotic selection is difficult without improving the ability to identify the pathogen and understand its susceptibility. ICMR’s 2025 guidance on validation of rapid diagnostics for pathogen identification and antimicrobial susceptibility testing reflects the growing importance of this capability.

The value of diagnostics lies in narrowing the gap between knowing that treatment is required and knowing what treatment is appropriate. Without that information, antibiotic use remains more dependent on uncertainty than the system would ideally allow.

Surveillance Provides the Feedback Loop

Then comes surveillance, which gives the entire system its feedback loop.

ICMR’s 2024 AMR Surveillance Network report analysed 99,027 culture-positive isolates collected during 2024. At the same time, the report cautioned that its tertiary-care hospital data should not be extrapolated directly to community-level AMR.

That limitation matters, but so does the information the surveillance network provides. Resistance patterns help inform clinical guidance, stewardship, infection control and policy. In other words, surveillance allows the system to see where resistance is moving and adjust its response accordingly.

From Factory to Patient

The antibiotic therefore has a considerably longer journey than the prescription suggests.

Manufacturers establish quality and consistency. Regulators establish the framework. Diagnostics help determine what needs to be treated. Doctors determine when and what to prescribe. Pharmacists reinforce appropriate use. Surveillance shows where resistance is moving.

Each function is distinct, but none operates in isolation. A weakness at one stage can place greater pressure on the stages that follow, while stronger controls across the chain give every subsequent decision a more reliable foundation.

World Pharmacists Day is therefore an opportunity to recognise the pharmacist within that chain, but also to look beyond the pharmacy counter. The effectiveness of an antibiotic is not protected by one intervention alone. It depends on the discipline maintained at every stage between the factory and the patient.